Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 27 Apr 2022
Enhertu granted breakthrough therapy designation in the US for patients with HER2 low metastatic breast cancer
27 April 2022 - Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a significant improvement in both progression-free ...
Posted by Michael Wonder on 26 Apr 2022
PBS brings hope to cancer patients
25 April 2022 - Late-stage breast cancer patients, many of them young women, will have access to a life-extending medication ...
Posted by Michael Wonder on 26 Apr 2022
With $35 million in funding, Waltz Health aims to lower drug prices working with – not against – the system
26 April 2022 - After a 30 year career as an executive at some of the country’s largest pharmacy benefit ...
Posted by Michael Wonder on 26 Apr 2022
Just one in five new cancer treatments available to Irish patients
26 April 2022 - Delays in reimbursing new treatments may affect course of illnesses, study says. ...
Posted by Michael Wonder on 26 Apr 2022
Amarin partner HLS Therapeutics completes reimbursement negotiations with Pan-Canadian Pharmaceutical Alliance for Vascepa (icosapent ethyl)
26 April 2022 - Amarin Corporation announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance for ...
Posted by Michael Wonder on 26 Apr 2022
Prothena receives FDA fast track designation for PRX012, a next generation anti-amyloid beta antibody under investigation for the treatment of Alzheimer’s disease
26 April 2022 - PRX012 is a potential best in class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase ...
Posted by Michael Wonder on 26 Apr 2022
Intra-Cellular Therapies announces FDA approval of new dosage strengths for Caplyta (lumateperone) for specific patient populations
25 April 2022 - Caplyta label now includes dosage recommendations for specific patient populations; those with moderate or severe hepatic ...
Posted by Michael Wonder on 26 Apr 2022
VBL Therapeutics receives FDA fast track designation for ofra-vec for the treatment of platinum-resistant ovarian cancer
26 April 2022 - OVAL Phase 3 top-line progression-free survival primary outcome data for ofra-vec expected in 2H 2022; with ...
Posted by Michael Wonder on 26 Apr 2022
Treadwell Therapeutics announces fast track designation granted by the FDA to CFI-400945 for the treatment of acute myeloid leukaemia
26 April 2022 - Treadwell Therapeutics announced today that the U.S. FDA has granted fast track designation to CFI-400945, a first ...
Posted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...
Posted by Michael Wonder on 26 Apr 2022
Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders
26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...
Posted by Michael Wonder on 26 Apr 2022
Pharming receives Promising Innovative Medicine designation for leniolisib from UK MHRA
26 April 2022 - A Promising Innovative Medicine designation is an early indication that leniolisib is a candidate for the ...
Posted by Michael Wonder on 26 Apr 2022
Insights from the March 2022 PBAC meeting (part 1)
26 April 2022 - Yesterday, we noted a recommendation rate of 78% which the highest value we have recorded since ...
Posted by Michael Wonder on 26 Apr 2022
Swissmedic has accepted the new oral edarvarone formulation for the treatment of ALS
25 April 2022 - Mitsubishi Tanabe Pharma announced that Swissmedic has accepted the filing for an investigational oral suspension formalation ...
Posted by Michael Wonder on 26 Apr 2022
ObsEva announces confirmation of positive CHMP opinion for linzagolix, an oral GnRH antagonist, for the treatment of uterine fibroids
25 April 2022 - ObsEva today announced that the CHMP of the EMA has confirmed its previously adopted positive opinion, ...